Search

Your search keyword '"Moses, AC"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Moses, AC" Remove constraint Author: "Moses, AC"
141 results on '"Moses, AC"'

Search Results

1. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE

2. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

3. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

4. Liraglutide and Renal Outcomes in Type 2 Diabetes

13. Exploring the wound healing potential of Ixora coccinea and Rhododendron arboreum formulation: integrating experimental and computational approaches.

14. Factors associated with burnout among healthcare providers in a rural context, South Africa.

15. Responses to COVID-19: The role of governance, healthcare infrastructure, and learning from past pandemics.

16. Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.

17. Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.

18. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

19. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

20. Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).

21. Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus.

22. Use of Poly-4-Hydroxybutyrate Mesh to Optimize Soft-Tissue Support in Mastopexy: A Single-Site Study.

23. The History of GalaFLEX P4HB Scaffold.

24. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

25. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

28. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

29. Diabetes prevention: perspectives and actions of one company.

30. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.

31. Comment on "The broken pen penalty" (Lakshmanadoss et al.).

32. Response to Swinnen et al.

33. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

34. Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.

35. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

36. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

37. Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?

38. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

39. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.

41. Impaired Response of Serum IGF-I Levels to Puberty in Previously Malnourished Adolescents.

42. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates.

43. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.

44. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.

45. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men.

46. Inhibition of Rev·RRE complexation by triplex tethered oligonucleotide probes.

47. Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour.

48. Short-term hyperthyroidism has no effect on leptin levels in man.

50. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation.

Catalog

Books, media, physical & digital resources